BACKGROUND: COVID19 convalescent plasma (CCP) is being extensively investigated as a treatment, with mixed results to date . Overall, there has been a generalized lack of appropriateness in prescriptions, which is termed patient-blood management in the field of transfusion medicine .
OBJECTIVES: We aimed at dissecting study design variables which could affect clinical outcome after CCP therapy . We focus here on variables such as pretransfusion antibody testing in recipients, dose adjustements, and antibody affinity measurements . SOURCES: We searched PubMed and preprint servers for relevant preclinical and clinical studies discussing each of these variables in the field of CCP therapy . CONTENT: We show evidences on how neglecting those variables has affected the outcomes of the vast majority of CCP clinical trials to date ..
IMPLICATIONS: A better understanding of such variables will improve the design of the next generation of CCP clinical trials . This will likely lead to better clinical outcomes and minimize risks from subneutralizing neutralizing antibody doses.